Centogene NV (Centogene NV) FCF Margin % : 0.00% (As of Jun. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Centogene NV FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Centogene NV's Free Cash Flow for the three months ended in Jun. 2023 was $0.00 Mil. Centogene NV's Revenue for the three months ended in Jun. 2023 was $0.00 Mil. Therefore, Centogene NV's FCF Margin % for the quarter that ended in Jun. 2023 was 0.00%.

As of today, Centogene NV's current FCF Yield % is -141.87%.

The historical rank and industry rank for Centogene NV's FCF Margin % or its related term are showing as below:

CNTG' s FCF Margin % Range Over the Past 10 Years
Min: -75.43 Med: -40.38 Max: -21.03
Current: -75.43

During the past 7 years, the highest FCF Margin % of Centogene NV was -21.03%. The lowest was -75.43%. And the median was -40.38%.

CNTG's FCF Margin % is ranked worse than
73.87% of 222 companies
in the Medical Diagnostics & Research industry
Industry Median: -10.405 vs CNTG: -75.43

Centogene NV FCF Margin % Historical Data

The historical data trend for Centogene NV's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centogene NV FCF Margin % Chart

Centogene NV Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

FCF Margin %

Get a 7-Day Free Trial

-40.38

-31.47

-21.03

-64.97

-60.21

Centogene NV Quarterly Data
	Dec17	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Jun23
FCF Margin %	Get a 7-Day Free Trial															6.74	-97.05	-54.66	-	-

Competitive Comparison of Centogene NV's FCF Margin %

For the Diagnostics & Research subindustry, Centogene NV's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Centogene NV's FCF Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Centogene NV's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Centogene NV's FCF Margin % falls into.

Centogene NV FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Centogene NV's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-30.277	/	50.289
	=	-60.21 %

Centogene NV's FCF Margin for the quarter that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	0	/	0
	=	%

Centogene NV FCF Margin % Related Terms

Thank you for viewing the detailed overview of Centogene NV's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Centogene NV (Centogene NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Centogene NV (NAS:CNTG) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

39K:Germany

Address

Am Strande 7, Rostock, MV, DEU, 18055

Website

https://www.centogene.com

Centogene NV is a United States-based company focused on transforming clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. The company operates in three segments: pharmaceutical, diagnostics, and COVID-19. Its pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. Its clinical diagnostics segment provides targeted genetic sequencing and diagnostics services to patients.